Objective
Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OPN-305) which has received OMP designation (EU/3/09/638) for use in the prevention of DGF. The scientific basis of this development is the inhibition of Toll-like receptor 2 (TLR2)-mediated ischaemic reperfusion injury which has a pivotal role in the pathogenesis of DGF and its sequelae. The MABSOT project is designed to progress the development of this OMP through Phase I and II clinical trial. The successful completion of the programme will allow the continued development of OPN-305 as an OMP for the treatment of DGF in a range of solid organ transplant situations. OPN-305 development will have significant benefit to these patients and health care providers in reducing the prolonged hospitalisation of these individuals, providing greater longevity associated with the transplanted organ and enhanced quality of life for these individuals.
Fields of science
Call for proposal
FP7-HEALTH-2010-single-stage
See other projects for this call
Funding Scheme
CP-FP - Small or medium-scale focused research projectCoordinator
2 Dublin
Ireland
Participants (9)
WC2R 2LS London
LN1 1XW Lincoln
3000 Leuven
Participation ended
08908 L'hospitalet De Llobregat
14021 Prague 4
NE1 7RU Newcastle Upon Tyne
9713 GZ Groningen
BT63 5QD Craigavon
08007 Barcelona